Vertex Pharmaceuticals has received a “Moderate Buy” consensus from 29 brokerages, with most analysts either holding or ...

In an era of rising complexity, rapid technology shifts, budget pressures, and uninsurable risks, traditional security approaches no longer suffice. Businesses need to understand where they're ...

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

This was the stock's second consecutive day of gains.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...